Safinamide (Xadago) will be listed on the PBS from 1 April for the treatment of Parkinson’s disease. Over 11,000 people with Parkinson are expected to benefit from the listing of the drug that would otherwise cost $1,400 per year for treatment without PBS subsidy. The listing follows a recommendation by the Pharmaceutical Benefits Advisory Committee ...
PBS listings for Parkinson’s and ALS treatments
By Michael Woodhead
19 Mar 2019